Streetbeat News

LXRX

Lexicon Pharmaceuticals, Inc.

https://www.lexpharma.com

Industry

Biotechnology

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain. The company has strategic collaboration and license agreements with Bristol-Myers Squibb Company, and Genentech, Inc. Lexicon Pharmaceuticals, Inc. was incorporated in 1995 and is headquartered in The Woodlands, Texas.

Open

0.36

Mkt cap

132M

Volume

High

0.37

P/E Ratio

-0.58

52-wk high

2.59

Low

0.36

Div yield

N/A

52-wk low

0.28

Fluor Corporation's shares fell by 7.7% following its Q4 results, with earnings beating estimates but sales missing expectations. Other stocks moved significantly in Tuesday's session, with notable gainers including TRxADE HEALTH, AgriFORCE Growing Systems, and Monopar Therapeutics, among others, due to various positive announcements. Losers included RAPT Therapeutics, MicroCloud Hologram, and Summit Therapeutics, primarily due to negative news or disappointing results.

Portfolio Pulse from Avi Kapoor

February 20, 2024 | 6:21 pm

As of Feb. 15, 2024, four health care stocks are considered overbought based on their RSI values, indicating potential short-term performance concerns. Solid Biosciences, Lexicon Pharmaceuticals, Ironwood Pharmaceuticals, and Dyne Therapeutics have shown significant gains but their RSI values suggest they may be overvalued. Investors focusing on momentum might consider reassessing these stocks.

Portfolio Pulse from Avi Kapoor

February 15, 2024 | 1:15 pm

Insiders at four companies, Marchex, Lexicon Pharmaceuticals, Blend Labs, and ESS Tech, have recently purchased shares, signaling potential confidence in their respective companies. These transactions involve penny stocks, with share prices under $2. Notable insider buying occurred following various company updates, including narrower-than-expected quarterly losses and upbeat sales reports.

Portfolio Pulse from Lisa Levin

November 14, 2023 | 11:45 am

Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) announced positive results from a post hoc analysis of the SCORED trial, showing early clinical benefits of INPEFA (sotagliflozin) in reducing heart failure and major adverse cardiovascular events (MACE) risks. The analysis, presented at the AHA Scientific Sessions 2023, indicated significant risk reductions as early as three months after treatment. INPEFA was approved by the FDA on May 26, 2023, for reducing cardiovascular risks in adults with heart failure or type 2 diabetes with additional risk factors.

Portfolio Pulse from Benzinga Newsdesk

November 12, 2023 | 10:16 pm

Lexicon Pharmaceuticals reported Q3 GAAP EPS of $(0.21), in line with analyst consensus. However, the company's sales of $162.00K missed the estimate of $2.06M by 92.14%. This represents a 61.54% decrease in losses from the same period last year and a 315.38% increase in sales from the same period last year. The company's cash and investments stand at $218.4M.

Portfolio Pulse from Benzinga Newsdesk

November 08, 2023 | 12:10 pm

Lexicon Pharmaceuticals (NASDAQ:LXRX) is set to release its latest quarterly earnings report on November 8, 2023. Analysts estimate an earnings per share (EPS) of $-0.21. The company's past performance shows a pattern of share price changes following earnings reports. The company's shares were trading at $1.29 as of November 6, and over the last 52-week period, shares are down 35.71%.

Portfolio Pulse from Benzinga Insights

November 07, 2023 | 4:02 pm

Lexicon Pharmaceuticals (NASDAQ:LXRX) announced that five data presentations related to INPEFA® (sotagliflozin) will be delivered during the American Heart Association Scientific Sessions 2023. The presentations will highlight the early clinical benefit of INPEFA for heart failure and atherosclerotic events, and the cost-effectiveness metrics associated with the use of INPEFA. The FDA recently approved INPEFA for the treatment of heart failure.

Portfolio Pulse from Benzinga Newsdesk

November 02, 2023 | 1:12 pm

Lexicon Pharmaceuticals announced that INPEFA has received coverage from Express Scripts on its basic and high performance formularies for commercially insured patients.

Portfolio Pulse from Benzinga Newsdesk

November 01, 2023 | 1:04 pm

Several stocks are experiencing significant pre-market trading movements. Cellectis S.A. (CLLS) surged 152% following strategic collaboration and investment agreements with AstraZeneca. Plus Therapeutics, Inc. (PSTV) rose 11.3% after announcing third-quarter financial results and a share repurchase program. On the downside, WeWork Inc. (WE) dipped 37.3% amid reports of a planned Chapter 11 bankruptcy filing. Paycom Software, Inc. (PAYC) fell 37.1% after reporting worse-than-expected third-quarter sales results and issuing below-estimate FY23 revenue guidance.

Portfolio Pulse from Lisa Levin

November 01, 2023 | 12:07 pm

Several US-listed companies including Paycom Software, Big 5 Sporting Goods Corporation, Yum China Holdings, Paycor HCM, Lexicon Pharmaceuticals, Match Group, Celestica, Zynex, and Advanced Micro Devices recorded losses in pre-market trading on Wednesday. This was due to various reasons such as worse-than-expected Q3 results, downgraded stocks, and issued FY23 revenue guidance below estimates.

Portfolio Pulse from Lisa Levin

November 01, 2023 | 10:17 am

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.